Teva Buys Drug Rival, Barr, for $ Billion #pharmaceutical #manufacturing #company

Posted On Nov 1 2016 by

#barr pharma # The New York Times Teva Buys Drug Rival, Barr, for $7.46 Billion July 19, 2008 Teva Pharmaceutical Industries said Friday that it would buy a rival generic drug maker, Barr Pharmaceuticals, for $7.46 billion to expand in both the United States and Europe. The deal is the latest in a wave of consolidation in the generic-drug sector that some analysts suspect will result in only a handful of major global players. Teva, the world’s largest generic drug company, plans to buy Barr for $66.50 a share in cash and stock. The price represents a 42 percent premium …


Astellas Pharma South East Europe #drug #manufacturer

Posted On Nov 1 2016 by

#astellas pharma # CHANGING TOMORROW™ We strive to be best-in-class in therapeutic areas where there is a vital need for treatments that improve and lengthen patients’ lives. Treatments that offer patients and their doctors genuinely new options for improving care. Astellas Pharma South East Europe is improving the future of patients in five key therapeutic areas Transplantation Innovative therapies in preventing organ rejection after transplantation Urology World-leading approach in R D to satisfy unmet patient needs in urological conditions Oncology Our commitment is to developing first-in-class and best-in-class therapies Anti-Infectives Addressing the complex challenges of serious fungal and bacterial infections …


Pharmaceutical Sales Interview #pharmaceuticals #news

Posted On Nov 1 2016 by

#pharmaceutical sales industry # job-interview.net’s exclusive practice interview with answers from the best selling Insider’s Guide to the World of Pharmaceutical Sales by Jane Williams. Review the description. A number of the underlined keywords have links to interview questions for that keyword or job function. Description: Promote pharmaceutical drug sales by forging relationships with physicians, hospitals and managed care organizations. Through one-on-one sales presentations, group discussions and educational programs, a sales representative presents the latest in medical news and treatment programs. Candidates require strong interpersonal skills. a team orientation and a mature, resilient outlook. Additional qualities include strong analytical and …


Stock: Teva Pharmaceutical Industries (TEVA) #pharma #dictionary

Posted On Nov 1 2016 by

#barr pharma # Teva Pharmaceutical Industries (TEVA) This article refers to the pharmaceutical company. For the Brazial real (BRL), see Brazilian Real (BRL) . Barr Pharmaceuticals (formerly BRL) was the parent company for Barr Laboratories and Duramed Pharmaceuticals, Inc. before being acquired by Teva Pharmaceutical Industries (TEVA). Through its two subsidiaries the company produces roughly 75 different generic pharmaceuticals and 19 brand name pharmaceutical products, largely focused on women’s health and birth control. On July 18th 2008, generic drug manufacturer Teva Pharmaceutical Industries (TEVA) announced it would buy Barr for $66.50 / share in cash and stock. Under the terms …


Barr Pharmaceutical #pharmaceutical #representative

Posted On Nov 1 2016 by

#barr pharma #Barr Pharmaceutical Barr Pharmaceuticals, Inc. is a holding company, whose principal subsidiaries, Barr Laboratories, Inc. and Duramed Pharmaceuticals, Inc. develop, manufacture and market generic and proprietary pharmaceuticals. The Company s product portfolio includes more than 100 generic and proprietary pharmaceutical products in core therapeutic categories including female healthcare (including oral contraceptive and hormone therapy products), oncology, cardiovascular, anti-infective and psychotherapeutic pharmaceuticals. The Company is listed on the New York Stock Exchange under the symbol BRL. With fiscal 2004 revenues of $1.3 billion, the Company currently manufactures and distributes more than 100 pharmaceutical products in core therapeutic categories including …


Astellas Pharma US, Inc #mitsubishi #pharma

Posted On Nov 1 2016 by

#astellas pharma # Astellas Pharma US, Inc. Latest Drug Information Updates Troxyca ER Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) is an extended-release, abuse-deterrent. Adlyxin Adlyxin (lixisenatide) is a once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist indicated. Xiidra Xiidra (lifitegrast) is a lymphocyte function-associated antigen-1 (LFA-1) antagonist indicated for the. Epclusa Epclusa (sofosbuvir and velpatasvir) is a nucleotide analog polymerase inhibitor and pan-genotypic NS5A. Byvalson Byvalson (nebivolol and valsartan) is a beta adrenergic blocker and an angiotensin II receptor blocker (ARB). Zinbryta Zinbryta (daclizumab) is an interleukin-2 receptor blocking antibody indicated for the treatment of relapsing. More. Was this page …


Future Of Pharmaceutical Companies #dabur #pharma

Posted On Nov 1 2016 by

#future of pharmaceutical industry # NOVARTIS CEO: Big Pharma Has To Move Beyond Just ‘Selling The Pill’ Swiss drugmaker Novartis recently lost patent protection on its best selling product, Diovan. They don’t have anything coming soon which looks like it could replace it. It’s a problem throughout the industry. Breakthroughs in huge markets, like that for Alzheimer’s treatment, haven’t materialized, despite billions in spending. That might be why Novartis picked an outsider, Joseph Jimenez, to lead it through this difficult time. Jimenez had previously worked in consumer goods. He discusses how he’s attempting to change the company in a Q …


Future of Pharmaceutical Industry – pharma innovation gaps, patent expiry, empty drug pipelines #rusan #pharma

Posted On Nov 1 2016 by

#future of pharmaceutical industry # The pharmaceutical industry is facing huge challenges – described in video above and in powerpoint slides below. Notes on content: Over the last five years there has been serious lack of innovation in pharma companies and product pipelines have been emptying. It takes up to 15 years and $1 billion in investment to bring a single new treatment to market, after which there may be as little as a decade left before patents expire. But before that happens there may be serious threats to the pharmaceutical industry from generic manufacturers. And at any point in …


Promentis Pharmaceuticals, Inc #global #pharm

Posted On Nov 1 2016 by

#schwarz pharma # Chad Beyer is President CEO of Promentis. He has nearly 20 years of experience in the research, discovery and business development of medications aimed to treat CNS and neurological disorders. Prior to joining Promentis, Dr. Beyer served as the Head of Neurochemistry and led the Psychiatry Task Force at Wyeth Pharmaceuticals in Princeton, NJ. During his career at Wyeth, Dr. Beyer led several early-stage drug discovery teams and managed a group responsible for contributing to the commercialization and life-cycle management of two blockbuster medications: Effexor® and Pristiq®. Dr. Beyer holds a Ph.D. in Neuropharmacology from LSU Medical …


Four scenarios for the future of the pharmaceutical industry #penn #pharma

Posted On Nov 1 2016 by

#future of pharmaceutical industry # Strathprints home Open Access Research under the microscope. The Strathprints institutional repository is a digital archive of University of Strathclyde research outputs. Strathprints serves world leading Open Access research by the University of Strathclyde, including research by the Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS), where research centres such as the Industrial Biotechnology Innovation Centre (IBioIC), the Cancer Research UK Formulation Unit, SeaBioTech and the Centre for Biophotonics are based. Four scenarios for the future of the pharmaceutical industry Bradfield, Ron M. and El-Sayed, Hany (2009) Four scenarios for the future of the pharmaceutical …